(redirected from disease progression)
Also found in: Dictionary, Thesaurus, Medical, Encyclopedia.
References in periodicals archive ?
"For MM patients receiving drug therapy, the economic burden of disease progression is substantial across all LOTs and this burden is generally greater in the era of novel treatments for relapse and refractory MM," the authors write.
In NSCLC, the recommended dose of KEYTRUDA is 200 mg administered as an intravenous infusion over 30 minutes every three weeks until disease progression, unacceptable toxicity, or up to 24 months in patients without disease progression.
The approval was based on pooled data from KEYNOTE-158 (cohort G) and KEYNOTE-028 (cohort C1), two multicenter, multi-cohort, non-randomised, open-label trials evaluating Keytruda in patients with SCLC who had disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy.
At a median follow-up of 16.1 months, the trial demonstrated a statistically significant and clinically meaningful improvement in progression-free survival in patients taking Calquence versus control, with the risk of disease progression or death reduced by 69%.
Greipp et al., "A high bone marrow plasma cell labeling index in stable plateau-phase multiple myeloma is a marker for early disease progression and death," Blood, vol.
Thus, the goal of this study was to systematically characterize the pattern of disease progression for patients with estrogen receptor positive metastatic breast cancer receiving ET.
The impact of baseline parameters on disease progression was assessed by bivariate and multivariate Cox regression analyses adjusted for clinical stage, preoperative PSA level, biopsy Gleason score, pathological stage, pathological Gleason score, lymph nodes, and surgical margins status.
We need a major breakthrough, and reducing disease progression a little bit is not a major breakthrough.
PSA doubling time, a measure of disease progression, was beneficially prolonged in 52% of patients after the initiation of metformin.
At 5 years, disease progression was associated with significantly greater volume declines in patients with disease than in those without in measurements of the whole brain (-3.8% vs.
The results showed that NSI-566 human spinal cord stem cells can be safely transplanted in both the lumbar and cervical spinal cord segments, did not accelerate disease progression, and warrant further study on dosing and therapeutic efficacy.
Importantly, as the "bell-shaped curve' associated with each intervention is likely due to disease progression, increasing the total cell dose, and applying multiple applications of these stem cells, may increase both the length and magnitude of the potential benefit.